title: Accuracy of optical frequency domain imaging for evaluation of coronary adventitial vasa vasorum formation after stent implantation in pigs and humans - a validation study - .
abstract: BACKGROUND
  Coronary adventitia harbors a wide variety of components, such as inflammatory cells and vasa vasorum (VV). Adventitial VV initiates the development of coronary artery diseases as an outside-in supply route of inflammation. We have recently demonstrated that drug-eluting stent implantation causes the enhancement of VV formation, with extending to the stent edges in the porcine coronary arteries, and also that optical frequency domain imaging (OFDI) is capable of visualizing VV in humans in vivo. However, it remains to be fully validated whether OFDI enables the precise measurement of VV formation in pigs and humans.
  
  
  RESULTS
  In the pig protocol, a total of 6 bare-metal stents and 12 drug-eluting stents were implanted into the coronary arteries, and at 1 month, the stented coronary arteries were imaged by OFDI ex vivo. OFDI data including the measurement of VV area at the stent edge portions were compared with histological data. There was a significant positive correlation between VV area on OFDI and that on histology (R=0.91, P<0.01). In the human protocol, OFDI enabled the measurement of the VV area at the stent edges after coronary stent implantation in vivo.
  
  
  CONCLUSIONS
  These results provide the first direct evidence that OFDI enables the precise measurement of the VV area in coronary arteries after stent implantation in pigs and humans.
authors.affiliation: Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine.
authors.forename: Kensuke
authors.initials: K
authors.lastname: Nishimiya
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Hironori
authors.initials: H
authors.lastname: Uzuka
authors.forename: Kazuma
authors.initials: K
authors.lastname: Oyama
authors.forename: Atsushi
authors.initials: A
authors.lastname: Tanaka
authors.forename: Akira
authors.initials: A
authors.lastname: Taruya
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Ogata
authors.forename: Michinori
authors.initials: M
authors.lastname: Hirano
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Shindo
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Hanawa
authors.forename: Yuhi
authors.initials: Y
authors.lastname: Hasebe
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Hao
authors.forename: Ryuji
authors.initials: R
authors.lastname: Tsuburaya
authors.forename: Jun
authors.initials: J
authors.lastname: Takahashi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Miyata
authors.forename: Kenta
authors.initials: K
authors.lastname: Ito
authors.forename: Takashi
authors.initials: T
authors.lastname: Akasaka
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shimokawa
mesh_terms: D063194:Adventitia / Q000098:blood supply* / Q000648:ultrastructure; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D023921:Coronary Stenosis / Q000503:physiopathology / Q000601:surgery*; D003331:Coronary Vessels / Q000187:drug effects / Q000503:physiopathology* / Q000648:ultrastructure; D018450:Disease Progression; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007368:Interferometry / Q000379:methods; D008297:Male; D008875:Middle Aged; D058426:Neointima / Q000473:pathology; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011184:Postoperative Period; D019919:Prosthesis Implantation; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D015607:Stents; D013552:Swine; D013556:Swine, Miniature; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D041623:Tomography, Optical Coherence / Q000379:methods*; D014651:Vasa Vasorum / Q000187:drug effects / Q000503:physiopathology*; D014657:Vasculitis / Q000150:complications / Q000473:pathology / Q000503:physiopathology
chemical_list: D010975:Platelet Aggregation Inhibitors; D000068338:Everolimus; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin; C518022:umirolimus; D020123:Sirolimus